- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare Nippon India Pharma Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.82 | 1.94 |
NAV | ₹499.13 | ₹37.57 |
Fund Started | 10 May 2004 | 25 Jun 2018 |
Fund Size | ₹8080.97 Cr | ₹4914.64 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.82
1.94
NAV
₹499.13
₹37.57
Fund Started
10 May 2004
25 Jun 2018
Fund Size
₹8080.97 Cr
₹4914.64 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 18.80% | 24.40% |
3 Year | 19.79% | 23.98% |
5 Year | 22.59% | 25.65% |
1 Year
18.80%
24.40%
3 Year
19.79%
23.98%
5 Year
22.59%
25.65%
Holding Analysis
Equity | 99.48% | 98.28% |
Cash | 0.52% | 1.72% |
Equity
99.48%
98.28%
Cash
0.52%
1.72%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.43% |
Divi's Laboratories Ltd. | 9.28% |
Lupin Ltd. | 7.27% |
Cipla Ltd. | 5.71% |
Apollo Hospitals Enterprise Ltd. | 5.31% |
Dr. Reddy's Laboratories Ltd. | 5.19% |
Glaxosmithkline Pharmaceuticals Ltd. | 3.61% |
Vijaya Diagnostic Centre Ltd. | 3.53% |
Abbott India Ltd. | 3.46% |
Medplus Health Services Ltd. | 3.41% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.50% |
Dr. Reddy's Laboratories Ltd. | 8.95% |
Cipla Ltd. | 8.85% |
Divi's Laboratories Ltd. | 6.71% |
Aurobindo Pharma Ltd. | 5.30% |
Lupin Ltd. | 4.73% |
Alkem Laboratories Ltd. | 4.42% |
Mankind Pharma Ltd. | 3.50% |
Gland Pharma Ltd. | 3.39% |
Zydus Lifesciences Ltd. | 3.10% |
Fund Manager
Name | Akshay Sharma | Dharmesh Kakkad |
Start Date | 01 Dec 2022 | 23 Feb 2021 |
Name
Akshay Sharma
Dharmesh Kakkad
Start Date
01 Dec 2022
23 Feb 2021
About Fund
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 10 May 2004 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
10 May 2004
25 Jun 2018